Orchid Pharma FY26: From Turnaround to Platform Creation

Standalone FY26 revenue from operations was INR 811 crore (FY25: INR 922 crore). EBITDA was INR 101 crore (FY25: INR 155 crore). PAT was INR 45 crore (FY25: INR 106 crore).

In Q4 FY26, total revenue was INR 251 crore, EBITDA was INR 42 crore, and PAT was INR 31 crore. The company highlighted recovery from Q3 FY26, when EBITDA was INR 13 crore and PAT was negative.

Management stated that for FY26, about 30% of revenue was from regulated markets and about 70% was from ROW, with fluctuations of about 5% historically.

The company plans 1,000 MT 7-ACA capacity at Kathua, Jammu, with about 75% intended for captive integration and about 25% for external monetization. Management said commissioning is targeted in Q1 calendar 2027.

Orchid plans to launch about 5 to 6 sterile products in the US by 2030. Management said initial ANDAs for the first two products will be filed through third-party CMOs to avoid delays from facility approval timing.

Management said the Cefiderocol facility is on track for commissioning by end of calendar 2026, with expected launch in Q2 or Q3 calendar 2027 subject to approvals. Capacity being built is 1 million vials.

Management stated EXBLIFEP is currently sold in India and Europe. Europe Q1 numbers were described as encouraging and about fourfold higher than the previous quarter, though still not financially meaningful.